In vitro study on the effects of iron sucrose, ferric gluconate and iron dextran on redox-active iron and oxidative stress

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 7, 2010, Pages 459-465

  Sturm, Brigitte ^a   Steinkellner, Hannes ^a   Ternes, Nina ^a   Goldenberg, Hans ^a   Scheiber Mojdehkar, Barbara ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Hemodialysis; Intravenous iron, cytotoxicity; Liver cells; Oxidative stress; Redox active iron

Indexed keywords

BUFFER; FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; IRON DEXTRAN; NEUTRAL RED; REACTIVE OXYGEN METABOLITE; DEXTRAN; FERRIC ION; FERRIC OXIDE, SACCHARATED; IRON; SACCHARIC ACID; SCAVENGER;

ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; HEMODIALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; BLOOD; CELL SURVIVAL; DRUG EFFECTS; HEPG2 CELL LINE; METABOLISM; PHYSIOLOGY;

CELL SURVIVAL; DEXTRANS; FERRIC COMPOUNDS; FREE RADICAL SCAVENGERS; GLUCARIC ACID; HEP G2 CELLS; HUMANS; IRON; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES;

EID: 77955390090     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296312     Document Type: Article

References (27)

1. Kooistra MP, Niemantsverdreit EC, van Es A, Mol-Beerman NM, Strycenberg A, Marx JJM. Iron absorption in erythropoietin- treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant. 1998;13:82-8.
2. Sunder-Plassmann G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant. 1995; 10:2070-6.
3. Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis. 1999; 34:21-8.
4. MacDougall IC. Present and future strategies in the treatment of renal anemia. Nephrol Dial Trans. 2001;16 (Suppl 5):S50-5.
5. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis. 2002;40:90-103.
6. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung.
7. Macdougall IC, Chandler G, Armstrong A, Breen C, Harchowal J, Calvill I. Characterisation of iron availability from three different IV iron preparations in dialysis patients. J AmSoc Nephrol. 1997;8:222.
8. Sturm B, Goldenberg H, Scheiber-Mojdehkar B. Transient increase of the labile iron pool in HepG2 cells by intravenous iron preparations. Eur J Biochem. 2003;270:3731-8.
9. Sturm B, Laggner H, Ternes N, Goldenberg H, Scheiber-Mojdehkar B. Intravenous iron preparations and ascorbic acid: effects on chelatable and bioavailable iron. Kidney Int. 2005;67:1161-70.
10. Scheiber-Mojdehkar B, SturmB, Plank L, Kryzer I., Goldenberg H. Influence of parenteral iron preparations on nontransferrin bound iron uptake, the iron regulatory protein and the expression of ferritin and the divalent metal transporter DMT-1 in HepG2 human hepatoma cells. Biochem.- Pharmacol. 2003;65:1973-8.
11. Van Wyck D, Anderson J, Johnson K. Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant. 2004;19:2674-5.
12. Esposito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Inv. 2002;32S:42-9.
13. Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int. 2004;66:1441-56.
14. Agarwal R. Transferrin saturation with intravenous irons: an in vitro study. Kidney Int. 2004;66:1139-44.
15. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 2004;65:2279-89.
16. Scheiber-Mojdehkar B, Lutzky B, Schaufler R, Sturm B, Goldenberg H. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation. J Am Soc Nephrol. 2004;15:1648-55.
17. Anraku M, Kitamura K, Shinohara A, Adachi M, Suenga A, Maruyama T, et al. Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int. 2004;66:841-9.
18. Mimic-Oka J, Savic-Radojevic A, Pljesa-Ercegovac M, Opacic M, Simic T, Dimkovic N, et al. Evaluation of oxidative stress after repeated intravenous iron supplementation. Ren Fail. 2005;27:345-51.
19. Bayes B, Pastor MC, Bonal J, Foraster A, Romero R. Oxidative stress, inflammation and cardiovascular mortality in haemodialysis-role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up. Nephrol Dial Transplant. 2006;21:984-90.
20. Schaller G, Scheiber-Mojdehkar B, Wolzt M, Puttinger H, Mittermayer F, Horl WH, et al. Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. Kidney Int. 2005;68:2814-22.
21. Zager RA, Johnson AC, Hanson SY, Lund S. Parenteral iron compounds sensitize mice to injury-initiated TNF-alpha mRNA production and TNF-alpha release. Am J Physiol Renal Physiol. 2005;288(2):F290-7.
22. Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003;102:2670-7.
23. Borenfreund E, Puerner JA. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett.1985; 24:119-24.
24. Danielson BG, Salmonson T, Derendorf H, Geisser P. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung. 1996;46:615-21.
25. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. 3rd ed. Oxford: Oxford Science Publications; 1999.
26. McCord JM. Iron, free radicals, and oxidative injury. Semin Hematol. 1998;35:5-12.
27. Pakkinen J, Von Bonsdorf L, Peltonen S, Grönhagen-Riska C, Rosenlöf K. Catalytically active iron and bacterial growth in serumof hemodialysis patients after i. v. iron-saccharate administration. Nephrol Dial Transplant. 2000;15: 1827-34.